In people with type 2 diabetes, a weekly injection of tirzepatide at 10 mg or 15 mg is associated with better function of insulin-producing cells in the pancreas, shown by specific biomarker changes,...
Mechanism
Synthesis from 1 study
Tirzepatide helps the pancreas make insulin more cleanly by reducing stress inside the insulin-producing cells, so they release less faulty insulin parts and more fully formed insulin. This happens because the drug activates two specific receptors that help the cells work better under high sugar...
Most probable mechanism
Tirzepatide binds to two specific receptors on insulin-producing cells in the pancreas, which helps these cells work more efficiently under high sugar conditions. This reduces a type of cellular strain that normally causes the cells to release immature insulin parts. As a result, more fully formed insulin is made and released, and fewer faulty parts leak out, which means the pancreas is under less stress and works better.
Tirzepatide binds to GIP and GLP-1 receptors on pancreatic beta cells
Receptor activation enhances intracellular cAMP/PKA and calcium signaling, increasing glucose-dependent insulin secretion
Reduced metabolic demand and improved protein folding capacity decrease endoplasmic reticulum stress in beta cells
Improved proinsulin-to-insulin conversion increases mature insulin output and reduces aberrant proinsulin secretion
Less supported by current evidence, but not ruled out
Tirzepatide also acts on fat tissue and the liver to increase signals that help the body use insulin better, which indirectly reduces the workload on insulin-producing cells by lowering blood sugar demands.
Tirzepatide activates GIP receptors on adipocytes, stimulating adiponectin secretion
Increased adiponectin enhances glucose uptake in adipose tissue and reduces hepatic lipid accumulation
Tirzepatide upregulates hepatic production of IGFBP-1 and IGFBP-2, modulating IGF-1 bioavailability
Elevated IGFBP-1 and IGFBP-2 enhance insulin sensitivity in liver and muscle tissue
Tirzepatide reduces the release of a hormone called glucagon from nearby cells in the pancreas, which lowers the liver's production of glucose, making it easier for insulin-producing cells to manage blood sugar levels.
Tirzepatide activates GLP-1 and GIP receptors on pancreatic alpha cells
Receptor activation inhibits glucagon secretion via cAMP-dependent and paracrine mechanisms
Reduced glucagon signaling lowers hepatic gluconeogenesis and glycogenolysis
Evidence from Studies
Supporting (1)
Community contributions welcome
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.